Phase I Study of MK-3475 in Combination With BCG for Patients With High Risk Superficial Bladder Cancer

Trial Profile

Phase I Study of MK-3475 in Combination With BCG for Patients With High Risk Superficial Bladder Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Bladder cancer vaccine
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Acronyms MARC
  • Most Recent Events

    • 27 Jun 2017 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.
    • 27 Jun 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
    • 09 Feb 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top